Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.

Bolen CR, Klanova M, Trneny M, Sehn LH, He J, Tong J, Paulson JN, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard MZ.

Haematologica. 2019 Nov 14. pii: haematol.2019.227892. doi: 10.3324/haematol.2019.227892. [Epub ahead of print]

2.

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.

Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E, Spielewoy N, Fingerle-Rowson G, Harbron C, Mundt K, Wassner-Fritsch E, Cheson BD.

Leukemia. 2020 Feb;34(2):522-532. doi: 10.1038/s41375-019-0559-9. Epub 2019 Aug 28.

PMID:
31462735
3.

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).

Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink AM, Tresckow J, Cramer P, Langerbeins P, Kutsch N, Humphrey K, Fingerle-Rowson G, Stilgenbauer S, Wendtner CM, Fischer K, Eichhorst B, Hallek M, Goede V.

Am J Hematol. 2019 Sep;94(9):1002-1006. doi: 10.1002/ajh.25561. Epub 2019 Jul 8.

PMID:
31222797
4.

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.

Klanova M, Oestergaard MZ, Trněný M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G.

Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.

PMID:
31053601
5.

Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.

Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C.

Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12.

6.

Macrophage migration inhibitory factor promotes renal injury induced by ischemic reperfusion.

Li JH, Tang Y, Lv J, Wang XH, Yang H, Tang PMK, Huang XR, He ZJ, Zhou ZJ, Huang QY, Klug J, Meinhardt A, Fingerle-Rowson G, Xu AP, Zheng ZH, Lan HY.

J Cell Mol Med. 2019 Jun;23(6):3867-3877. doi: 10.1111/jcmm.14234. Epub 2019 Apr 9.

7.

Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.

Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S.

Leukemia. 2019 Sep;33(9):2183-2194. doi: 10.1038/s41375-019-0446-4. Epub 2019 Mar 25.

8.

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.

Jamois C, Gibiansky E, Gibiansky L, Buchheit V, Sahin D, Cartron G, Marcus R, Hiddemann W, Seymour JF, Strefford JC, Hargreaves CE, Meneses-Lorente G, Frey N, Fingerle-Rowson G.

Br J Clin Pharmacol. 2019 Jul;85(7):1495-1506. doi: 10.1111/bcp.13920. Epub 2019 May 17.

9.

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.

Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M.

Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7.

10.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM.

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19. No abstract available.

11.

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K.

Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.

12.

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.

Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study.

Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8. Erratum in: Lancet Oncol. 2019 Apr 29;:.

PMID:
30309758
13.

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD.

Leuk Lymphoma. 2019 Apr;60(4):894-903. doi: 10.1080/10428194.2018.1515940. Epub 2018 Oct 2.

14.

Blocking Macrophage Migration Inhibitory Factor Protects Against Cisplatin-Induced Acute Kidney Injury in Mice.

Li J, Tang Y, Tang PMK, Lv J, Huang XR, Carlsson-Skwirut C, Da Costa L, Aspesi A, Fröhlich S, Szczęśniak P, Lacher P, Klug J, Meinhardt A, Fingerle-Rowson G, Gong R, Zheng Z, Xu A, Lan HY.

Mol Ther. 2018 Oct 3;26(10):2523-2532. doi: 10.1016/j.ymthe.2018.07.014. Epub 2018 Jul 17.

15.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE.

J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.

PMID:
29856692
16.

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH.

J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.

PMID:
29584548
17.

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.

Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M.

Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18.

PMID:
29255066
18.

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W.

N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.

19.

Combination therapy with the type II anti-CD20 antibody obinutuzumab.

Klein C, Bacac M, Umana P, Fingerle-Rowson G.

Expert Opin Investig Drugs. 2017 Oct;26(10):1145-1162. doi: 10.1080/13543784.2017.1373087. Review.

PMID:
28845710
20.

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.

Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH.

J Clin Oncol. 2017 Nov 1;35(31):3529-3537. doi: 10.1200/JCO.2017.73.3402. Epub 2017 Aug 10.

PMID:
28796588
21.

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.

Tobinai K, Klein C, Oya N, Fingerle-Rowson G.

Adv Ther. 2017 Feb;34(2):324-356. doi: 10.1007/s12325-016-0451-1. Epub 2016 Dec 21. Review.

22.

Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin.

Brocks T, Fedorchenko O, Schliermann N, Stein A, Moll UM, Seegobin S, Dewor M, Hallek M, Marquardt Y, Fietkau K, Heise R, Huth S, Pfister H, Bernhagen J, Bucala R, Baron JM, Fingerle-Rowson G.

FASEB J. 2017 Feb;31(2):526-543. doi: 10.1096/fj.201600860R. Epub 2016 Oct 19.

23.

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S.

J Clin Oncol. 2016 Nov 1;34(31):3758-3765. doi: 10.1200/JCO.2016.67.1305.

PMID:
27573660
24.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD.

Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.

PMID:
27345636
25.

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.

Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G, Berge C, Sahin D, Press O, Sehn L.

Leuk Lymphoma. 2017 Feb;58(2):372-381. Epub 2016 Jun 24.

PMID:
27339738
26.

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.

Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V.

Leukemia. 2016 Aug;30(8):1763-6. doi: 10.1038/leu.2016.41. Epub 2016 Mar 4. No abstract available.

27.

Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.

Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G.

Leuk Lymphoma. 2016 May;57(5):1130-9. doi: 10.3109/10428194.2015.1070151. Epub 2015 Nov 20.

PMID:
26584689
28.

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.

Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP.

Blood. 2016 Jan 7;127(1):79-86. doi: 10.1182/blood-2015-03-634394. Epub 2015 Oct 15.

29.

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M, Salles G, Cartron G.

Blood. 2015 Dec 10;126(24):2646-9. doi: 10.1182/blood-2015-09-670802. Epub 2015 Oct 7. No abstract available.

30.

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW.

J Clin Oncol. 2015 Oct 20;33(30):3467-74. doi: 10.1200/JCO.2014.59.2139. Epub 2015 Aug 17.

31.

Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE.

Ji N, Kovalovsky A, Fingerle-Rowson G, Guentzel MN, Forsthuber TG.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 6;2(5):e139. doi: 10.1212/NXI.0000000000000139. eCollection 2015 Oct.

32.

Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer.

Mawhinney L, Armstrong ME, O' Reilly C, Bucala R, Leng L, Fingerle-Rowson G, Fayne D, Keane MP, Tynan A, Maher L, Cooke G, Lloyd D, Conroy H, Donnelly SC.

Mol Med. 2015 Apr 16;20:729-35. doi: 10.2119/molmed.2014.00136.

33.

Macrophage migration inhibitory factor is essential for osteoclastogenic mechanisms in vitro and in vivo mouse model of arthritis.

Gu R, Santos LL, Ngo D, Fan H, Singh PP, Fingerle-Rowson G, Bucala R, Xu J, Quinn JM, Morand EF.

Cytokine. 2015 Apr;72(2):135-45. doi: 10.1016/j.cyto.2014.11.015. Epub 2015 Jan 31.

34.

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.

Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M.

Leukemia. 2015 Jul;29(7):1602-4. doi: 10.1038/leu.2015.14. Epub 2015 Jan 30. No abstract available.

PMID:
25634683
35.

The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury.

Qi D, Atsina K, Qu L, Hu X, Wu X, Xu B, Piecychna M, Leng L, Fingerle-Rowson G, Zhang J, Bucala R, Young LH.

J Clin Invest. 2014 Aug;124(8):3540-50. doi: 10.1172/JCI73061. Epub 2014 Jul 1.

36.

Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.

Schmidt C, Fingerle-Rowson G, Boehme A, Brendel K, Fischer R, Gonnermann M, Höhler T, Kegel T, Kellermann L, Nusch A, Pönisch W, Wendtner C, Dreyling M.

Leuk Lymphoma. 2015 Mar;56(3):694-702. doi: 10.3109/10428194.2014.928935. Epub 2014 Aug 19.

PMID:
24937122
37.

Macrophage migration inhibitory factor inhibits the antiinflammatory effects of glucocorticoids via glucocorticoid-induced leucine zipper.

Fan H, Kao W, Yang YH, Gu R, Harris J, Fingerle-Rowson G, Bucala R, Ngo D, Beaulieu E, Morand EF.

Arthritis Rheumatol. 2014 Aug;66(8):2059-70. doi: 10.1002/art.38689.

38.

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H.

Blood. 2014 May 22;123(21):3247-54. doi: 10.1182/blood-2014-01-546150. Epub 2014 Mar 20.

PMID:
24652989
39.

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.

Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M.

Leukemia. 2013 Sep;27(9):1949-52. doi: 10.1038/leu.2013.190. Epub 2013 Jun 21. No abstract available.

40.

CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia.

Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L, Breuer A, Crispatzu G, Rosen N, Landwehr T, Lilienthal N, Möllmann M, Montesinos-Rongen M, Heukamp L, Dürig J, Hallek M, Fingerle-Rowson G, Herling M.

Blood. 2013 May 16;121(20):4126-36. doi: 10.1182/blood-2012-11-466250. Epub 2013 Apr 1.

PMID:
23547049
41.

Role of migratory inhibition factor in age-related susceptibility to radiation lung injury via NF-E2-related factor-2 and antioxidant regulation.

Mathew B, Jacobson JR, Siegler JH, Moitra J, Blasco M, Xie L, Unzueta C, Zhou T, Evenoski C, Al-Sakka M, Sharma R, Huey B, Bulent A, Smith B, Jayaraman S, Reddy NM, Reddy SP, Fingerle-Rowson G, Bucala R, Dudek SM, Natarajan V, Weichselbaum RR, Garcia JG.

Am J Respir Cell Mol Biol. 2013 Aug;49(2):269-78. doi: 10.1165/rcmb.2012-0291OC.

42.

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.

Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M.

Cancer. 2013 Jun 15;119(12):2258-67. doi: 10.1002/cncr.27972. Epub 2013 Mar 19.

43.

Macrophage-derived, macrophage migration inhibitory factor (MIF) is necessary to induce disease in the K/BxN serum-induced model of arthritis.

Singh A, Leng L, Fan J, Gajda M, Bräuer R, Fingerle-Rowson G, Bucala R, Illges H.

Rheumatol Int. 2013 Sep;33(9):2301-8. doi: 10.1007/s00296-013-2713-4. Epub 2013 Mar 17.

44.

Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.

Reinart N, Nguyen PH, Boucas J, Rosen N, Kvasnicka HM, Heukamp L, Rudolph C, Ristovska V, Velmans T, Mueller C, Reiners KS, von Strandmann EP, Krause G, Montesinos-Rongen M, Schlegelberger B, Herling M, Hallek M, Fingerle-Rowson G.

Blood. 2013 Jan 31;121(5):812-21. doi: 10.1182/blood-2012-05-431452. Epub 2012 Nov 1.

PMID:
23118218
45.

Brain miffed by macrophage migration inhibitory factor.

Savaskan NE, Fingerle-Rowson G, Buchfelder M, Eyüpoglu IY.

Int J Cell Biol. 2012;2012:139573. doi: 10.1155/2012/139573. Epub 2012 Sep 3.

46.

Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis.

Adamali H, Armstrong ME, McLaughlin AM, Cooke G, McKone E, Costello CM, Gallagher CG, Leng L, Baugh JA, Fingerle-Rowson G, Bucala RJ, McLoughlin P, Donnelly SC.

Am J Respir Crit Care Med. 2012 Jul 15;186(2):162-9. doi: 10.1164/rccm.201110-1864OC. Epub 2012 May 16.

47.

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M.

J Clin Oncol. 2012 Mar 20;30(9):980-8. doi: 10.1200/JCO.2011.36.9348. Epub 2012 Feb 13.

PMID:
22331940
48.

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM.

J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23. Erratum in: J Exp Med. 2012 Mar 12;209(3):640.

49.

The outcome of renal ischemia-reperfusion injury is unchanged in AMPK-β1 deficient mice.

Mount PF, Gleich K, Tam S, Fraser SA, Choy SW, Dwyer KM, Lu B, Denderen BV, Fingerle-Rowson G, Bucala R, Kemp BE, Power DA.

PLoS One. 2012;7(1):e29887. doi: 10.1371/journal.pone.0029887. Epub 2012 Jan 9.

50.

Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis.

Herrero LJ, Nelson M, Srikiatkhachorn A, Gu R, Anantapreecha S, Fingerle-Rowson G, Bucala R, Morand E, Santos LL, Mahalingam S.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12048-53. doi: 10.1073/pnas.1101089108. Epub 2011 Jul 5.

Supplemental Content

Loading ...
Support Center